IFNA1 and lymphoma: Recently, a study of the FL mouse model with a new vaccine including IFN-DCs loaded with apoptotic lymphoma cells demonstrated that lenalidomide improves the therapeutic effect of an interferon-α-dendritic cell-based lymphoma vaccine, which may lead to evaluation of the combination in clinical applications [165].